Actividad antineoplásica de la riproximina, una proteína citotóxica inactivadora de ribosomas tipo II – Una revisión
Resumen
El estudio presenta una síntesis del conocimiento a través de los hallazgos en la literatura sobre la riproximina y su actividad antineoplásica, basada en una revisión en las bases de datos Embase, Scopus, PubMed-Medline y Web of Science. Mediante la aplicación de criterios de selección, se seleccionaron 9 estudios, que después de ser analizados, forman parte de la revi- sión. Los estudios sobre la riproximina son escasos pero en algunos se ha informado sobre la actividad antineoplásica contra las líneas celulares de cáncer de hígado y en la cepa Suit2-007 de adenocarcinoma pancreático, lo que demuestra el potencial antineoplásico, por lo cual se necesita información sobre la aplicación de la proteína en terapias contra el cáncer para proponer una nueva clase de terapias antineoplásicas.
Recibido: 04/05/2023 Aceptado: 31/07/2023Palabras clave
Texto completo:
PDFReferencias
World Health Organization. Global Cancer Observatory. Cancer
Tomorrow. Lyon, France: WHO, 2020. Disponible en: https://
gco.iarc.fr/tomorrow/en/dataviz/isotype
MMAN Ranjha, B Shafique, L Wang, S Irfan, MN Safdar, MA
Murtaza, HR Nadeem. A comprehensive review on phytochemis-
try, bioactivity and medicinal value of bioactive compounds of
pomegranate (Punica granatum). Adv. Trad. Med., 23(1), 37-57
(2023).
V Mishra, R Mishra, RS Shamra. Ribosome inactivating proteins–
An unfathomed biomolecule for developing multi-stress tolerant
transgenic plants. Int. J. Biol. Macromol, 210, 107-122 (2022).
F Stirpe, MG Battelli. Ribosome-inactivating proteins: progress
and problems. Cell. Mol. Life Sci., 63, 1850-1866 (2006).
R Kumar, A Bhattacharjee, S Tiwari. Plant-derived ribosome-in-
activating proteins involved in defense against plant viruses. Eur.
J. Plant Pathol., 162, 1-23 (2022):
M Puri, I Kaur, MA Perugini, RC Gupta. Ribosome-inactivating
proteins: current status and biomedical applications. Drug Discov.
Today, 17(14), 774-783 (2012).
MR Hartley, JM Lord. Cytotoxic ribosome-inactivating lectins
from plants. Biochim. Biophys. Acta - Proteins and Proteomics,
(1-2), 1-14 (2004).
FWMB Preijers. Rationale for the clinical use of immunotoxins:
monoclonal antibodies conjugated to ribosome-inactivating pro-
teins. Leuk. Lymphoma, 9(4-5), 293-304 (1993).
C Voss, MR Eyol, E Berger. Identification of potent anticancer
activity in Ximenia americana aqueous extracts used by African
traditional medicine. Toxicol. Appl. Pharmacol., 211(3), 177-
(2006).
C Horrix, Z Raviv, E Flescher, C Voss, MR Berger. Plant ribo-
some-inactivating proteins type II induce the unfolded protein re-
sponse in human cancer cells. Cell. Mol. Life Sci., 68, 1269-1281
(2011).
RF Celedonio, ACF Queiroga, WF Celedonio, JF Felício, XBL de
Queiroz, YS de Oliveira, JF do Amaral. Propriedades antidiabéti-
cas das plantas medicinais do gênero Bauhinia: revisão integra-
tiva. Rev. Fitos., 1(1) (2023). https://doi.org/10.32712/2446-
2023.1399
R Whittemore. Combining in nursing research: methods and im-
plications. Nurs. Res., 54(1), 56-62 (2005).
M Ouzzani, H Hammady, Z Fedorowicz, A Elmagarmid. Ray-
yan—a web and mobile app for systematic reviews. Syst. Rev.,
(210) (2016). https://doi.org/10.1186/s13643-016-0384-
A Pervaiz, T Saleem, K Kanwal, SM Raza, S Iqbal, M Zepp, MR
Berger. Expression profiling of anticancer genes in colorectal can-
cer patients and their in vitro induction by riproximin, a ribosomal
inactivating plant protein. J. Cancer Res. Clin. Oncol., 1-13,
(2022). https://doi.org/10.1007/s00432-022-04410-6
MN Sagini, KD Klika, A Orry, M Zepp, J Mutiso, MR Berger.
Riproximin exhibits diversity in sugar binding and modulates
some metastasis-related proteins with lectin like properties in pan-
creatic ductal adenocarcinoma. Front. Pharmacol., 11, e549804
(2020). https://doi.org/10.3389/fphar.2020.549804
A Murtaja, E Eyol, J Xiaoqi, MR Berger, H Adwan. The ribosome
inhibiting protein riproximin shows antineoplastic activity in ex-
perimental pancreatic cancer liver metastasis. Oncol. Lett., 15(2),
-1448 (2018). https://doi.org/10.3892/ol.2017.7526
A Pervaiz, M Zepp, H Adwan, MR Berger. Riproximin modulates
multiple signaling cascades leading to cytostatic and apoptotic ef-
fects in human breast cancer cells. J. Cancer Res. Clin. Oncol.,
, 135-147 (2016). https://doi.org/10.1007/s00432-015-2013-3
Pervaiz A, Adwan H, Berger MR. Riproximin: A type II ribosome
inactivating protein with anti-neoplastic potential induces
IL24/MDA-7 and GADD genes in colorectal cancer cell lines. Int.
J. Oncol, 47(3), 981-990 (2015). https://doi.org/10.3892/ijo.
3073
H Adwan, A Murtaja, K Kadhim Al-Taee, A Pervaiz, T Hielscher,
MR Berger. Riproximin’s activity depends on gene expression
and sensitizes PDAC cells to TRAIL. Cancer Biol. Ther., 5(9),
-1197 (2014). https://doi.org/10.4161/cbt.29503
J Saenger, M Leible, MH Seelig, MR Berger. Chemoembolization
of rat liver metastasis with irinotecan and quantification of tumor
cell reduction. J. Cancer Res. Clin. Oncol., 130, 203-210 (2004).
https://doi.org/10.1007/s00432-003-0523-x
H Bayer, K Essig, S Stanzel, M Frank, JC Gildersleeve, MR Ber-
ger, C Voss. Evaluation of riproximin binding properties reveals a
novel mechanism for cellular targeting. J. Biol. Chem., 287(43),
–35886 (2012). https://doi.org/10.1074/jbc.M112.368548
F Stirpe. Ribosome-inactivating proteins: from toxins to useful
proteins. Toxicon, 67, 12–16 (2013). https://doi.org/10.1016/
j.toxicon.2013.02.005
C Voss, E Eyol, M Frank, CW Lieth, C Voss, MR Berger. Identi-
fication and characterization of riproximin, a new type II ribo-
some‐inactivating protein with antineoplastic activity from Xime-
nia americana. The FASEB Journal, 20(8), 1194-1196 (2006).
http://www.fasebj.org/cgi/doi/10.1096/fj.05–5231fje
H Bayer, N Ey, A Wattenberg, C Voss, MR Berger. Purification
and characterization of riproximin from Ximenia americana fruit
kernels. Protein Expr. Purif., 82(1), 97-105 (2012). https://doi.
org/10.1016/j.pep.2011.11.018
MR Hartley, JM Lo+rd. Cytotoxic ribosome-inactivating lectins
from plants. Biochim. Biophys. Acta, 1701(1-2), 1–14 (2004).
https://doi.org/10.1016/j.bbapap.2004.06.004
LM Roberts, JM Lord. Ribosome-inactivating proteins: entry into
mammalian cells and intracellular routing. Mini Rev. Med.
Chem., 4(5), 505-512 (2004). https://doi.org/10.2174/13895570
LF Reyes. Proteínas inativadoras de ribossomos: identificação de
novas proteínas e estudos de interação da cadeia-A da pulchellina
(PAC) com monocamada de Langmuir. (Tese de doutorado). São
Carlos, Instituto de Física de São Carlos. Universidade de São
Paulo, 34 p. (2011). https://doi.org/10.11606/T.76.2011.tde-
-114447
M Zeng, M Zheng, D Lu, J Wang, W Jiang, O Sha. Anti-tumor
activities and apoptotic mechanism of ribosome-inactivating pro-
teins. Chin. J. Cancer, 34(3), 1-10 (2015). https://doi.org/10.
/s40880-015-0030-x
H Adwan. Riproximin Is A New Plat Lectin With Antineoplastic
Activity Aganist In Rat Pancreatic Cancer. Qatar Found. Annual
Res. Forum, 1, 126 (2013). https://doi.org/10.5339/qfarf.2013.BIOP-0126
H Nie, X Liu, Y Zhang, T Li, C Zhan, W Huo, Y Li. Specific N-
glycans of hepatocellular carcinoma cell surface and the abnormal
increase of core-α-1, 6-fucosylated triantennary glycan via N-
acetylglucosaminyltransferases-IVa regulation. Sci. Rep., 5(1),
(2015). https://doi.org/10.1038/srep16007
S Bharadwaj, SS Rathore, PC Ghosh. Enhancement of the cyto-
toxicity of liposomal ricin by the carboxylic ionophore monensin
and the lysosomotropic amine NH4Cl in Chinese hamster ovary
cells. Int. J. Toxicol., 25(5), 49-59 (2006). https://doi.org/10.
/10915810600846195
IE Herawati, R Lesmana, J Levita, A Subarnas. Cytotoxicity,
apoptosis, migration inhibition, and autophagy-induced by crude
ricin from Ricinus communis seeds in A549 lung cancer cell lines.
Med. Sci. Monit. Basic Res., 28, e936683 (2022). https://doi.org/
12659/MSMBR.936683
L Citores, R Munoz, MA Rojo, P Jimenez, JM Ferreras, T Girbes.
Evidence for distinct cellular internalization pathways of ricin and
nigrin b. Cell. Mol. Biol., 49, OL461–465 (2003).
Depósito Legal: PPI200602ME2232
ISSN: 1856-5301
Todos los documentos publicados en esta revista se distribuyen bajo una
Licencia Creative Commons Atribución -No Comercial- Compartir Igual 4.0 Internacional.
Por lo que el envío, procesamiento y publicación de artículos en la revista es totalmente gratuito.